Growing Geriatric Population is Anticipated to Proliferate the Global Dyslipidemia market

The growing prevalence of cardiovascular disease (CVD) among the populace, rising cholesterol abnormalities in developed and lipid lowering drugs in the developing economies, booming aging populace and surging obesity rate in the people due to inactive lifestyle and poor dietary habit of the people is projecting a optimistic impact on the growth of the market in the forecasted period. Moreover, escalating funding towards the research and development of novel drugs, increasing number of dyslipidemias among patients with hypertension and diabetes along with augmenting government investment towards R&D activities for the development of novel drugs, escalating rate of diagnosis test among patient is imposing a lucrative opportunity for the growth of dyslipidemia market in the forthcoming period.

 

Based on Type, Drug segment captured the majority market share in the Global Dyslipidemia market in 2019. Statins dominated the drug segment market due to boost in the demand for statin drugs such as Lipitor and Crestor to reduce the symptoms of cholesterol levels in the body

 

Based on End-user, Hospitals & specialty centers and Medical laboratories accounted the highest market share in the Global Dyslipidemia market in 2019. The growth of the segment is attributed to significant rise in the diagnosis rate of dyslipidemia in hospitable and specialty centers along with burgeoning investment towards the development in cholesterol lowering drugs, rising R&D activities in the medical laboratories in therapeutics area. Thus, this is anticipated to propel the market growth in the coming years.

 

North America captured the largest market share in Global Dyslipidemia market in 2019. United states dominated the North America dyslipidemia market on account of biotechnological developments, growing health care concern about the treatment of dyslipidemia along with surging investment towards improvement in health care infrastructure and burgeoning incidence rates of diabetes and obesity among people due to unhealthy lifestyle.

The key players with a considerable market share in the Global Dyslipidemia market are Merck, Pfizer, Sanofi, Bristol-Myers Squibb, Abionyx (Cerenis), Cipla, Daewoong Pharmaceutical, Daiichi Sankyo, Novartis, Amgen etc.